Table 3.
Summary of ocular adverse events reported in at least 5% of patients
| Netarsudil/latanoprost FDC n = 482 |
Netarsudil n = 498 |
Latanoprost n = 488 |
|
|---|---|---|---|
| Eye disorders, n (%) | |||
| Conjunctival hyperemia | 283 (58.7) | 234 (47.0) | 108 (22.1) |
| Cornea verticillate | 74 (15.4) | 58 (11.6) | 0 |
| Conjunctival hemorrhage | 52 (10.8) | 72 (14.5) | 5 (1.0) |
| Eye pruritus | 37 (7.7) | 23 (4.6) | 5 (1.0) |
| Punctate keratitis | 17 (3.5) | 27 (5.4) | 14 (2.9) |
| Visual acuity reduced | 25 (5.2) | 21 (4.2) | 9 (1.8) |
| Lacrimation increased | 25 (5.2) | 28 (5.6) | 1 (0.2) |
| Administration site conditions, n (%) | |||
| Instillation site pain | 97 (20.1) | 83 (16.7) | 33 (6.8) |
| Instillation site discomfort | 25 (5.2) | 23 (4.6) | 5 (1.0) |
In the system organ class or preferred term, n is the number of patients with at least one adverse event; % is based on the number of patients (n) in a given treatment group for the safety population
When reporting incidence, a patient was only counted once if they ever experienced an event within the system organ class or individual preferred term. System organ class and preferred term are based on Version 19.0 of the MedDRA coding dictionary